Introduction of a Novel Topoisomerase-I Inhibitor ADC Platform

Time: 4:30 pm
day: Day Two


  • Discussing design and characterization of payloads and ADCs including potency, specificity, bystander activity, and biophysical characteristics
  • Evaluating ADCs against multiple tumor targets demonstrating strong anti-tumor activity in xenograft models
  • Sharing encouraging data in multiple preclinical tolerability studies